Rubinstein Files Form 4 for Adaptive Biotechnologies

TL;DR

**Insider Julie Rubinstein filed a Form 4 for Adaptive Biotechnologies, but the summary doesn't show transaction details.**

AI Summary

This Form 4 filing indicates that Julie Rubinstein, a reporting person for Adaptive Biotechnologies Corp (NASDAQ: ADPT), filed a statement of changes in beneficial ownership of securities on March 23, 2026, for a transaction that occurred on March 19, 2026. While the filing confirms her status and the reporting period, it does not detail specific transactions like buys or sells. This matters to investors because it signals that an insider's ownership structure may have changed, and further investigation into the full filing is needed to understand the nature and impact of any transactions on their investment.

Why It Matters

This filing confirms an insider's reporting obligation but lacks transaction details, requiring investors to review the full document to understand any changes in ownership that could signal insider sentiment.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the lack of transaction details in this summary means investors don't yet know if there was a significant buy or sell, which could be a medium risk if it's a large sale.

Analyst Insight

Investors should access the full Form 4 document to determine the specific nature of the transaction (e.g., stock options exercised, shares bought, or sold) to understand the implications for Adaptive Biotechnologies Corp's stock.

Key Players & Entities

• RUBINSTEIN JULIE (person) — Reporting Person
• Adaptive Biotechnologies Corp (company) — Issuer
• 0001780664 (dollar_amount) — CIK for RUBINSTEIN JULIE
• 0001478320 (dollar_amount) — CIK for Adaptive Biotechnologies Corp
• 2026-03-23 (dollar_amount) — Filing Date
• 2026-03-19 (dollar_amount) — Period of Report

FAQ

Key Financial Figures

• $12.99 — ple transactions at prices ranging from $12.99 to $13.53, inclusive. The reporting per
• $13 — ctions at prices ranging from $12.99 to $13.53, inclusive. The reporting person und
• $13.23 — ple transactions at prices ranging from $13.23 to $13.59, inclusive. The reporting per
• $13.51 — ple transactions at prices ranging from $13.51 to $14.07, inclusive. The reporting per
• $14 — ctions at prices ranging from $13.51 to $14.07, inclusive. The reporting person und

Filing Documents

• form4.html (4)
• form4.xml (4) — 21KB
• 0001780664-26-000014.txt ( ) — 23KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * RUBINSTEIN JULIE (Last) (First) (Middle) C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1165 EASTLAKE AVENUE EAST (Street) SEATTLE WASHINGTON 98109 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ ADPT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) President and COO 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/19/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/19/2026 M (1) 14,722 A $ 6.55 509,642 D Common Stock 03/19/2026 S (1) 19,060 D $ 13.18 (2) 490,582 D Common Stock 03/20/2026 M (1) 3,939 A $ 6.55 494,521 D Common Stock 03/20/2026 M (1) 10,783 A $ 7.27 505,304 D Common Stock 03/20/2026 S (1) 19,060 D $ 13.37 (3) 486,244 D Common Stock 03/23/2026 M (1) 14,722 A $ 7.27 500,966 D Common Stock 03/23/2026 S (1) 19,060 D $ 13.83 (4) 481,906 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 6.55 03/19/2026 M (1) 14,722 (5) 02/07/2028 Common Stock 14,722 $ 0 3,939 D Stock Option (right to buy) $ 6.55 03/20/2026 M (1) 3,939 (5) 02/07/2028 Common Stock 3,939 $ 0 0 D Stock Option (right to buy) $ 7.27 03/20/2026 M (1) 10,783 (5) 02/07/2029 Common Stock 10,783 $ 0 214,217 D Stock Option (right to buy) $ 7.27 03/23/2026 M (1) 14,722 (5) 02/07/2029 Common Stock 14,722 $ 0 199,495 D Explanation of Responses: 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. 2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. 3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within t

View Full Filing

View this 4 filing on SEC EDGAR